UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 1418, 2014

Chelsea TherapEUtics International, Ltd.

(Exact name of registrant as specified in its charter)

Delaware

000-51462

20-3174202

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer ID Number)

3530 Toringdon Way, Suite 200, Charlotte, North Carolina 28277

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (704) 341-1516

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~o ~~7.01~~Soliciting ~~Regulation~~material FDpursuant ~~Disclosure~~to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Ino ~~response~~Pre-commencement tocommunications ~~abnormal trading~~pursuant ~~activity~~to inRule ~~its~~14d-2(b) ~~common~~under ~~stock, Chelsea Therapeutics International, Ltd. announced on February 14, 2014 that no decision regarding its Northera NDA has been received from~~ the ~~U.S.~~Exchange ~~Food~~Act &(17 ~~Drug~~CFR ~~Administration as of 11:45 AM on such date~~240.14d-2(b))

~~Signature~~o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Pursuant~~Item to8.01 ~~the~~Other ~~requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~Events.

	CHELSEA THERAPEUTICS INTERNATIONAL, LTD.
	By:	/s/ J. Nick Riehle
		J. Nick Riehle
		Chief Financial Officer
Dated: February 14, 2014

On February 18, 2014, Chelsea Therapeutics International, Ltd. issued a press release announcing that the U.S. Food and Drug Administration had granted accelerated approval of Northera™ (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01.

Financial Statements and Exhibits.

(d)

Exhibits

	Exhibit No.		Description

	99.1		Press release dated February 18, 2014.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CHELSEA THERAPEUTICS INTERNATIONAL, LTD.

	By:	/s/ J. Nick Riehle
		J. Nick Riehle
		Chief Financial Officer

Dated: February 18, 2014

Exhibit Index

Exhibit No.		Description

99.1		Press release dated February 18, 2014.

Filing Compare · Chelsea Therapeutics International, Ltd.